CoChat

Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis

Open access

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

Body weight loss of ≥ 10% improves the metabolic derangements and liver disease in the majority of non-alcoholic steatohepatitis (NASH) patients, suggesting metabolic modulators may be effective in controlling disease. The pharmacodynamics of ALT-801, a GLP-1/glucagon receptor dual agonist optimized for NASH and weight loss, were compared to semaglutide (GLP-1 receptor agonist) and elafibranor (peroxisome proliferator-activated receptor, PPAR-α/δ, agonist) in a biopsy-confirmed, diet-induced obese (DIO) mouse model of NASH (DIO-NASH). Male C57BL/6J mice were fed Amylin Liver NASH (AMLN) diet for 32 weeks. Animals with biopsy-confirmed steatosis and fibrosis received ALT-801, semaglutide, elafibranor, or vehicle daily for 12 weeks while maintained on the AMLN diet. Study endpoints included body and liver weight, liver and plasma total cholesterol and triglycerides, plasma aminotransferases, histological analysis of liver steatosis, inflammation (galectin-3) and fibrosis (collagen type 1 alpha 1), and evaluation of individual animal changes in composite Non-alcoholic Fatty Liver Disease Activity Score (NAS), and fibrosis stage. ALT-801 demonstrated significant reductions in body weight (approx. 25%), plasma aminotransferases, plasma total cholesterol and liver triglycerides/total cholesterol in conjunction with improved liver steatosis, with greater reductions (p < 0.05) compared to semaglutide and elafibranor. ALT-801 significantly reduced the inflammation marker galectin-3 and the fibrosis marker collagen type 1 alpha 1 vs. vehicle (p < 0.05), with ALT-801 producing greater reductions in galectin-3 vs. elafibranor (p < 0.05). Importantly, all animals treated with ALT-801 significantly improved composite NAS compared to the active controls. This study provides evidence for a potential role for ALT-801 in the therapeutic treatment of NASH.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-022-10577-2

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Pharmacokinetic behavior of ALT-801 and semaglutide in C57Bl/6J mice following subcutaneous administration. Mice received a single s.c. injection of ALT-801 or semaglutide at 10 nmol/kg and key PK characteristics were calculated. Compared to semaglutide, for ALT-801 the data indicate a longer Tmax with a substantially lower Cmax and an overall delayed PK envelope, having a similar AUC.
Figure 1 Pharmacokinetic behavior of ALT-801 and semaglutide in C57Bl/6J mice following subcutaneous administration. Mice received a single s.c. injection of ALT-801 or semaglutide at 10 nmol/kg and key PK characteristics were calculated. Compared to semaglutide, for ALT-801 the data indicate a longer Tmax with a substantially lower Cmax and an overall delayed PK envelope, having a similar AUC.CC BY · PubMed Central
Figure 2 Body weight of treatment groups. DIO-NASH mice were treated daily with vehicle (s.c.), ALT-801 (5 and 10 nmol/kg, s.c.), elafibranor (78 μmol/kg, oral) or semaglutide (10 nmol/kg, s.c.). Body weight was recorded daily. For ALT-801 and semaglutide, rapid body weight decreases occurred within 1–2 weeks and stabilized. Elafibranor (PPAR-α/δ agonist) causes weight loss in rodents but not in clinical trials. On day 63 vehicle animals were mis-dosed with ALT-801 10 nmol/kg, causing a rapid ~ 8% body weight decrease, which resolved over a period of days. ALT-801 treatment (10 nmol/kg) reduced body weight to the lean normal range (~ 30 g; − 25%). Data are expressed as mean ± SEM (n = 11–12). ***p ≤ 0.001 vs. vehicle control.
Figure 2 Body weight of treatment groups. DIO-NASH mice were treated daily with vehicle (s.c.), ALT-801 (5 and 10 nmol/kg, s.c.), elafibranor (78 μmol/kg, oral) or semaglutide (10 nmol/kg, s.c.). Body weight was recorded daily. For ALT-801 and semaglutide, rapid body weight decreases occurred within 1–2 weeks and stabilized. Elafibranor (PPAR-α/δ agonist) causes weight loss in rodents but not in clinical trials. On day 63 vehicle animals were mis-dosed with ALT-801 10 nmol/kg, causing a rapid ~ 8% body weight decrease, which resolved over a period of days. ALT-801 treatment (10 nmol/kg) reduced body weight to the lean normal range (~ 30 g; − 25%). Data are expressed as mean ± SEM (n = 11–12). ***p ≤ 0.001 vs. vehicle control.CC BY · PubMed Central
Figure 3 Effects of treatment on liver fat content and liver weight. (A) Representative H&E-stained images of liver morphology at the end of treatment period for vehicle, semaglutide, elafibranor, and ALT-801 10 nmol/kg treated DIO-NASH animals (magnification 20×, scale bar = 100 µm). (B) Mean total liver fat content (mg). (C) Mean terminal liver weight (g). Data are expressed as mean ± SEM (n = 11–12). **p < 0.01, ****p < 0.0001 vs. vehicle control.
Figure 3 Effects of treatment on liver fat content and liver weight. (A) Representative H&E-stained images of liver morphology at the end of treatment period for vehicle, semaglutide, elafibranor, and ALT-801 10 nmol/kg treated DIO-NASH animals (magnification 20×, scale bar = 100 µm). (B) Mean total liver fat content (mg). (C) Mean terminal liver weight (g). Data are expressed as mean ± SEM (n = 11–12). **p < 0.01, ****p < 0.0001 vs. vehicle control.CC BY · PubMed Central
Figure 4 Treatment effects on NAFLD Activity Score and fibrosis stage. (A) Change in mean non-alcoholic fatty liver disease activity score (NAS). Significance is vs. ALT-801 10 nmol/kg. (B) Change in individual NAS. (C) Change in mean fibrosis stage. (D) Change in individual fibrosis stages. The points at each scoring step are slightly shifted to allow visual separation of the animals. This presentation is only for visualization purposes and does not reflect any difference in score. ****p < 0.0001.
Figure 4 Treatment effects on NAFLD Activity Score and fibrosis stage. (A) Change in mean non-alcoholic fatty liver disease activity score (NAS). Significance is vs. ALT-801 10 nmol/kg. (B) Change in individual NAS. (C) Change in mean fibrosis stage. (D) Change in individual fibrosis stages. The points at each scoring step are slightly shifted to allow visual separation of the animals. This presentation is only for visualization purposes and does not reflect any difference in score. ****p < 0.0001.CC BY · PubMed Central
Figure 5 Treatment effects on liver inflammation, fibrosis and lipids. Shown are changes in liver histological and biochemical markers following 12 weeks of treatment with the study drugs. (A) Change in terminal liver Col1A1. (B) Change in terminal liver Gal-3. Quantification of Col1A1 and Gal-3 was determined by histomorphometry. (C) Total liver cholesterol (TC) content. (D) Total liver triglycerides (TG). Data are expressed as mean ± SEM (n = 11–12). *p < 0.05, **p < 0.01, ****p < 0.0001 vs. vehicle control.
Figure 5 Treatment effects on liver inflammation, fibrosis and lipids. Shown are changes in liver histological and biochemical markers following 12 weeks of treatment with the study drugs. (A) Change in terminal liver Col1A1. (B) Change in terminal liver Gal-3. Quantification of Col1A1 and Gal-3 was determined by histomorphometry. (C) Total liver cholesterol (TC) content. (D) Total liver triglycerides (TG). Data are expressed as mean ± SEM (n = 11–12). *p < 0.05, **p < 0.01, ****p < 0.0001 vs. vehicle control.CC BY · PubMed Central
Figure 6 Effects of treatment on plasma liver markers. (A) Plasma ALT. (B) Plasma AST. (C) Plasma TG. (D) Plasma TC. Data are expressed as mean ± SEM (n = 11–12). One-way ANOVA with Dunnett’s adjustment for multiplicity. **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. vehicle control.
Figure 6 Effects of treatment on plasma liver markers. (A) Plasma ALT. (B) Plasma AST. (C) Plasma TG. (D) Plasma TC. Data are expressed as mean ± SEM (n = 11–12). One-way ANOVA with Dunnett’s adjustment for multiplicity. **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. vehicle control.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 55

Metadata

Authors
Nestor, J. J., Parkes, D., Feigh, M., Suschak, J. J., & Harris, M. S.
Affiliations
  • Altimmune (United States) (US)
  • Gubra (Denmark) (DK)
Corresponding author
Harris, M. Scott
Venue
Scientific Reports
Published
2022-04-23
Volume
12
Issue
1
Pages
6666-6666
ISSN
2045-2322 (ISSN-L)
OpenAlex
W4225589081
Cited by
53
References
43
Citations by year
2026: 10 · 2025: 10 · 2024: 18 · 2023: 12 · 2022: 3
FWCI
7.76
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Spitfire Pharma Inc
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
nonalcoholic steatohepatitis, diet-induced obesity, semaglutide, elafibranor, hepatic steatosis, liver fibrosis, galectin-3, collagen type I alpha 1, transaminases, weight loss, mouse model
MeSH terms
Transaminases, Animals, Cholesterol, Collagen, Disease Models, Animal, Glucagon, Inflammation, Interleukin-2, Liver, Liver Cirrhosis, Male, Mice, Inbred C57BL, Mice, Obese, Obesity, Receptors, Antigen, T-Cell, Recombinant Fusion Proteins, Triglycerides, Receptors, Glucagon, Galectin 3, Mice, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis. https://app.cochat.ai/papers/10.1038/s41598-022-10577-2
The paper
Nestor, J. J., Parkes, D., Feigh, M., Suschak, J. J., & Harris, M. S. (2022). Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis. Scientific Reports. https://doi.org/10.1038/s41598-022-10577-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.